Secondary Philadelphia chromosome after non-myeloablative peripheral blood stem cell transplantation for a myelodysplastic syndrome in transformation [1]

Bone Marrow Transplantation

Volumn 33, Issue 2, 2004, Pages 247-249

  Prebet, T ^a   Michallet, A S ^a   Charrin, C ^a   Hayette, S ^a   Magaud, J P ^a   Thiebaut A ^a   Michallet, M ^a   Nicolini, F E ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CHIMERA; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSFORMATION; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MYELODYSPLASTIC SYNDROME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

FEMALE; GENES, ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHILADELPHIA CHROMOSOME;

EID: 0842323946     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704308     Document Type: Letter

References (12)

1. Smadja N, Krulik M, De Gramont A et al. Acquisition of a Philadelphia chromosome concomitant with transformation of a refractory anemia into an acute leukemia. Cancer 1985; 55: 1477-1481.
2. Mozziconacci MJ, Sainty D, Gabert JC et al. The Philadelphia chromosome as a secondary abnormality in two cases of acute myeloid leukemia. Br J Haematol 1998; 102: 873-875.
3. Pedersen-Bjergaard J, Brondum-Nielsen K, Karle H, Johansson B. Chemotherapy-related - late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors? Leukemia 1997; 11: 1571-1574.
4. Lesesve JF, Troussard X, Bastard C et al. p190bcr/abl rearrangement in myelodysplastic syndromes: two reports and review of the literature. Br J Haematol 1996; 95: 372-375.
5. Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program) 2001, 375-391.
6. Gabert J, Beillard E, van der Veden VHJ et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer Program. Leukemia, (in press).
7. Roumier C, Daudignon A, Soenen V et al. p190 bcr-abl rearrangement: a secondary cytogenetic event in some chronic myeloid disorders? Haematologica 1999; 84: 1075-1080.
8. Drummond MW, Lush CJ, Vickers MA et al. Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia 2003; 17: 463-465.
9. Giles FJ, Koeffler HP. Secondary myelodysplastic syndromes and leukemias. Curr Opin Hematol 1994; 1: 256-260.
10. Biernaux C, Loos M, Sels A et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-3122.
11. Bose S, Deininger M, Gora-Tybor J et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362-3367.
12. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.